X Close
TMCnet - World's Largest Communications and Technology Community



Research and Markets: Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Report
[March 03, 2014]

Research and Markets: Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Report

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/cgkhnl/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014" report to their offering.

'Spinal Muscular Atrophy (SMA (News - Alert)) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


- A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) .

- A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-pecific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Key Topics Covered:


Spinal Muscular Atrophy (SMA) Overview

Therapeutics Development

Late Stage Products

Clinical Stage Products

Early Stage Products

Drug Profiles

olesoxime - Drug Profile

valproate sodium + [levocarnitine] - Drug Profile

ISIS-SMNRx - Drug Profile

sodium phenylbutyrate - Drug Profile

PF-06687859 - Drug Profile

SMN-2 - Drug Profile

MotorGraft - Drug Profile

AAV9-SMN Gene Therapy - Drug Profile

Motor Neuron Precursor Cells - Drug Profile

PTK-SMA-2 - Drug Profile

NXD-30001 - Drug Profile

DNA Oligonucleotides For Spinal Muscular Atrophy - Drug Profile

RE-003 - Drug Profile

fasudil - Drug Profile

Drug for Spinal Muscular Atrophy - Drug Profile

ND-602 - Drug Profile

RNase H-Active Antisense Oligos - Drug Profile

Indoprofren Analog - Drug Profile

Agrin Biologic For SMA - Drug Profile

sodium phenylbutyrate - Drug Profile

Drugs for Motor Neuron Diseases - Drug Profile

PMO-25 - Drug Profile

INT-41 - Drug Profile

Antisense Molecules - Drug Profile

Featured News & Press Releases


Companies Mentioned

Genzyme Corporation

F. Hoffmann-La Roche Ltd.

Isis Pharmaceuticals, Inc.

Pfizer Inc.

Paratek Pharmaceuticals, Inc.

Neurotune AG

Trophos SA

Nexgenix Pharmaceuticals, LLC


Vybion, Inc.

California Stem Cell, Inc.

OrphageniX, Inc.

Retrophin, LLC

Neurodyn Inc.

Cellular Biomedicine Group, Inc.

gmp-orphan SAS (News - Alert)

For more information visit http://www.researchandmarkets.com/research/cgkhnl/spinal_muscular

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

[ Back To TMCnet.com's Homepage ]

Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.


© 2015 Technology Marketing Corporation. All rights reserved | Privacy Policy